Merkel cell carcinoma (MCC) is a rare aggressive disease of the skin. It usually appears as a painless pink, red, purple, or skin-colored lump on the head and neck region. MCC develops from a type of skin cells located in the basal layer of the epidermis called Merkel cells. Some key symptoms of MCC include red nodules on skin, lumps or bumps on skin, persistent itching, and changes to existing moles or spots. The rising prevalence of MCC worldwide is mainly attributed to factors like increased sun exposure and weakened immunity among the aging population.
The Global Merkel Cell Carcinoma Market is estimated to be valued at USD 2.51 Bn in 2024 and is expected to reach USD 3.38 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.
Key Takeaways
Key players operating in the Merkel cell carcinoma market are Merck & Co., Inc., Amgen Inc., Oncovir, Inc., and Vaccinex, Inc.
Key opportunities in the market include promising immunotherapy and combination therapy approaches explored in recent clinical trials along with continued investment in understanding MCC disease biology.
With increasing R&D focus, the Merkel Cell Carcinoma Market major pharmaceutical companies are anticipated to expand their reach beyond key markets like North America and Europe in coming years to tap higher growth opportunities across Asia Pacific and Latin America.
Market Drivers
One of the key drivers for the Merkel cell carcinoma market is the increasing incidence of MCC worldwide. According to statistics, the annual incidence of MCC in the US increased from 0.17 per 100,000 people in 1986 to 0.44 per 100,000 people in 2006. This rise is primarily attributed to growing older adult population base and extensive UV exposure from recreational and occupational activities.
Market Restrain
High cost of treatment poses a major challenge for the widespread adoption of advanced Merkel cell carcinoma treatment options like immunotherapy and targeted therapies. According to some estimates, the total cost of 5-year cancer care for an MCC patient ranges between US$ 150,000 to US$ 200,000 in the US. Limited reimbursement support for novel premium-priced drugs especially in developing regions can hamper market potential to some extent over the forecast period.
Segment Analysis
The Merkel cell carcinoma market is divided into two main segments based on type of treatment- chemotherapy and immunotherapy & targeted therapy. Chemotherapy is currently dominating the market as it is the conventional first line treatment regime for Merkel cell carcinoma. However, immunotherapy & targeted therapy segment is expected to witness highest growth during the forecast period. This is because of increasing adoption of PD-1 and PDL-1 inhibitors such as avelumab and pembrolizumab as first line treatment which provides long term remission and better survival rates than chemotherapy.
Global Analysis
Geographically, North America holds the largest share in the Merkel cell carcinoma treatment market and is expected to witness the highest growth during the forecast period. This is due to factors such as growing prevalence of Merkel cell carcinoma in the US, favorable reimbursement policies, increasing demand for advanced therapeutics and presence of major market players in the region. Europe is second largest market driven by high healthcare spending and supportive government initiatives for cancer research. The Asia Pacific region is projected to be the fastest growing market led by improving access to advanced treatment options, rising healthcare spending of patients and increasing awareness about rare cancers. However, market growth in underdeveloped regions remains restrained due to low healthcare penetration and lack of insurance coverage.
Get This Report in Japanese Language: メルケル細胞癌市場
Get This Report in Korean Language: 메르켈 세포 암 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
Market HighlightsThe Global Surgical Retractors Market held a market value of USD 1,103 Million in 2017 and is projected to grow at a CAGR of 7.8% over the forecast period.An increasing number of surgical procedures leading to increase demand of surgical retractors.
Surgical retractors are one of the important surgical instruments which is used to separate the edges of the wound or surgical incision.
Due to increasing prevalence of obesity across the globe many of the companies are in the race to introduce better treatment for obesity.
Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth.
As per the data by the Office for National Statistics, in 2016, the gross domestic expenditure on research and development (R) was Euro 33.1 billion (USD 35.2 billion) in the UK.
Europe is expected to hold the second-largest position in the global surgical retractors market owing to the presence of strong academic & research base and availability of funding for research in the European countries.
Global Merkel Cell Carcinoma Market Research Report: By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), Treatment (Surgery, Radiation Therapy, Chemotherapy), End User (Hospitals & Clinics, Diagnostic Centers) – Forecast till 2027Market HighlightsIncreasing prevalence of Merkel cell carcinoma and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period.
However, the high cost of therapeutics and related side effects along with the lack of awareness and low per capita healthcare expenditures in the developing economies restrains the market growth.
The chemotherapy segment is sub-segmented into etoposide, cisplatin, and others.
On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, research organization, and others.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5343Regional AnalysisThe Americas dominate the global Merkel cell carcinoma market.
Presence of a well-developed healthcare sector and high per capita healthcare expenditures provides favorable backgrounds for market growth within the region.
Followed by the Americas, Europe leads the Merkel cell carcinoma market.
Market HighlightsFactors driving the growth of the market for the merkel cell carcinoma treatment are the increase in the market for the treatment of merkel cell carcinoma worldwide will affect the demand for innovative drugs for the treatment of metastatic merkel cell carcinoma In addition, high acceptance of immunotherapy and favorable reimbursement are considered to be positive indicators for the growth of the treatment of advanced merkel cell carcinoma.
In comparison, with extended sun exposure, the chance of contracting the disease increases.
Factors such as the growing prevalence of neuroendocrine carcinoma and the increasing geriatric population are also expected to be the key factors over the projected timeframe for business growth.
In addition, growing R investment by key industry participants, rising MCC mortality rates, and rising healthcare spending are some of the factors driving market growth during the projected period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5343However, it is assumed that the market for the treatment of Merkel cell carcinoma is greatly hampered by the high cost of treatment coupled with the cessation of late-stage clinical trials.
It is estimated that the associated side effects, lack of awareness, and low per capita healthcare spending in middle and low-income countries will limit market growth during the forecast period.Segmental AnalysisBased on diagnosis, treatment, and end users, the global market for Merkel cell carcinoma is segmented.
The segment of chemotherapy is sub-segmented to include etoposide, cisplatin, and others.
Merkel Cell Carcinoma (MCC) Treatment Market: IntroductionMerkel cell carcinoma, also known as neuroendocrine carcinoma of the skin, is a rare and aggressive type of skin cancer that develops from the top layers of the skin.
The disease is caused due to prolonged exposure to the sun, weak immunity, or due to idiopathic reasons.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=56184Merkel cell carcinoma (MCC) is a rare disease in which malignant cancer cells form in the skin.
Merkel cell carcinoma grows rapidly into a metastasize at an early stage, by spreading to nearby lymph nodes or skin in distant parts of the body, lungs, brain, bones, or other organs.Several tests and procedures can be carried to examine the skin to detect and diagnose carcinoma cells; however, there are certain factors or effects of prognosis and treatment options that decrease the chance of recovery.
Request COVID Analysis on Merkel Cell Carcinoma (MCC) Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=56184 Key Drivers, Restraints, and Opportunities of Global Merkel Cell Carcinoma (MCC) Treatment MarketIncreasing cases of MCC is a prominent factor propelling the global Merkel cell carcinoma market.
In May 2017, researchers of Fred Hutchison University and the University of Washington in Seattle reported the results of a small study combining Avelumab with two other treatments.
For instance, in December 2018, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., undertook a phase 3 open-label, single-arm study to evaluate the efficacy of pembrolizumab as first-line therapy in the participants with advanced Merkel cell carcinoma.
This report studies the global market size of Merkel Cell Carcinoma Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Merkel Cell Carcinoma Treatment in these regions.
This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.
Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin.
The key manufacturers in the Merkel Cell Carcinoma Treatment include
Market Size Split by Type
Market Size Split by Application
